Vyriad, Inc. has completed its $85 million Series B financing round with a final $25 million tranche to support the upcoming clinical debut of VV169, its lead in vivo CAR T-cell therapy. The Rochester-based biotechnology company plans to initiate first-in-human trials in 2026 for relapsed or treatment-refractory multiple myeloma. This development marks one of the earliest clinical-stage entries for in vivo CAR T delivery, building on momentum from preclinical results disclosed at the 2025 ASH Annual Meeting.

With the broader industry still experimenting with how to scale cellular immunotherapies beyond hospital-bound manufacturing, Vyriad’s lentiviral platform promises a major modality shift — moving from lab-based T-cell engineering to direct in-body programming. The financing sets the stage for proof-of-concept validation of a technology that, if successful, could redefine CAR T economics and accessibility.

How Vyriad’s platform differs from conventional ex vivo CAR T approaches

What makes Vyriad’s approach noteworthy is its attempt to bypass ex vivo manipulation entirely. Traditional autologous CAR T therapy involves extracting patient T cells, modifying them outside the body, and re-infusing them — a process that is costly, labor-intensive, and logistically fragile. Vyriad’s strategy instead relies on a single intravenous administration of a lentiviral vector, LV-169, that delivers a BCMA-targeting CAR gene directly into T cells in vivo.

The company’s lentiviral vector is anchored by an engineered G protein to improve stability in blood, boost transduction efficiency, and reduce off-target immunogenicity. These properties allow the therapy to target T cells in their natural lymphoid niche and express the CAR gene selectively — all without relying on lab-based reprogramming.

VV169 is therefore part of a growing class of gene therapy constructs designed to engineer immune cells within the patient, potentially eliminating the need for apheresis, GMP cell manufacturing, and cryopreservation. This could not only reduce costs but expand access for patients who are too sick to wait for cell processing or who lack infrastructure for CAR T administration.

What the preclinical data reveals — and what remains unproven

The second key milestone backing Vyriad’s clinical plans is its data presented at ASH 2025, where the company disclosed full preclinical results for VV169. In humanized mouse models, a single IV dose of VV169 eliminated disseminated OPM-2 tumors in 100 percent of treated mice across all dose levels, including the lowest. Mice remained tumor-free for 84 days and resisted re-challenge, suggesting strong persistence and memory formation.

Importantly, the treatment appeared safe: inflammatory cytokines such as IL-6 and TNFα remained low, mitigating one of the central risks in CAR T therapy — cytokine release syndrome (CRS). Only interferon gamma showed expected elevations during T-cell expansion. Additionally, Vyriad’s construct used a T-cell-specific promoter, preventing expression of CAR protein on the virus itself and reducing the risk of transducing malignant cells.

While these data are promising, they remain early-stage and preclinical. The leap from mouse models to human biology — especially in a heavily pretreated multiple myeloma population — is nontrivial. Industry observers note that many gene therapy platforms demonstrate strong early efficacy only to encounter durability or safety concerns in Phase 1 trials. The real test for VV169 will be whether its targeted delivery can maintain efficacy and avoid toxicity in a diverse patient population with variable immune environments.

Why in vivo CAR T is being closely watched across oncology

Vyriad is not the only player pushing in vivo reprogramming. Companies such as ImmPACT Bio, Umoja Biopharma, and Capstan Therapeutics are also pursuing platforms that skip traditional manufacturing. Recent preclinical and Phase 1 efforts have shown early signs that direct T-cell engineering in the body is possible, although results remain fragmented.

Still, the rationale is strong: by removing the infrastructure bottlenecks of current CAR T workflows, in vivo methods could democratize access. Payers and clinicians have long criticized CAR T’s high price tags and logistical hurdles. If Vyriad can demonstrate scalable, safe, and durable responses from a single outpatient infusion, the implications for oncology access models could be profound.

However, adoption risk remains. The field has seen enthusiasm around oncolytic viruses and gene therapies that later faced development headwinds around immune clearance, transduction variability, and long-term integration safety. Lentiviral platforms also come with their own risks, including insertional mutagenesis, although newer designs have improved safety profiles.

Manufacturing scalability and platform generalizability remain open questions

Vyriad’s proprietary G protein-based lentiviral system is being positioned as the backbone not only for VV169 but for a broader pipeline of in vivo cell therapies. The company has three retargeting strategies in development: direct covalent display (being clinically translated through VV169), trimeric adapter proteins, and modular covalent display using SPY-tag technology.

All three approaches aim to precisely target T cells in vivo while simplifying production. Vyriad claims that these methods have shown promising stability, freeze–thaw tolerance, and receptor specificity — critical traits for enabling centralized manufacturing and off-the-shelf delivery.

However, manufacturing scalability remains a key unknown. Most in vivo approaches are still produced in limited GMP runs, and the challenge of making viral vectors at commercial scale, while preserving purity and consistency, has tripped up past gene therapy developers. Moreover, while VV169 targets BCMA — a well-characterized antigen in multiple myeloma — the adaptability of this delivery system to other cell types or indications is still hypothetical.

What regulators and clinicians are likely to watch in the first-in-human study

The first-in-human clinical trial, expected to begin in 2026, will be a defining moment. Clinicians and regulators will be watching for three key things: safety signals related to cytokine storms or off-target integration, persistence of CAR expression over time, and early signs of anti-tumor activity.

Because VV169 uses a lentiviral vector, the possibility of long-term integration into host genomes adds complexity to trial oversight. While lentiviral vectors have a better safety record than earlier gamma-retroviral constructs, any risk of insertional oncogenesis will need to be rigorously ruled out. The use of a T-cell-specific promoter may help mitigate this, but comprehensive biodistribution and integration site analyses will be critical.

On the clinical side, multiple myeloma remains a competitive and fast-moving indication. Any therapeutic lag or safety concern could give an edge to other in vivo or ex vivo players. Still, Vyriad’s platform could earn credibility if it demonstrates early success in targeting and persistence — two of the most valuable characteristics for next-gen immune therapies.

Why the Vyriad financing matters in a cooling biotech environment

In a year marked by cautious capital deployment across biotech, Vyriad’s ability to secure $85 million in Series B funding is a signal of investor belief in the viability of in vivo delivery. The final tranche was led by Harry Stine of Stine Seed Farms, a notable backer in agricultural biotechnology, with support from several family offices.

The investment validates Vyriad’s dual-track model: a proprietary in vivo platform and active pharma collaborations. The company has partnered with Regeneron Pharmaceuticals and Novartis in related programs, which suggests confidence in its vector engineering beyond VV169. These alliances may also offer clinical development leverage as Vyriad prepares to scale operations ahead of its Phase 1 trial.

While many oncology startups have pivoted toward antibody–drug conjugates or targeted protein degradation, Vyriad is doubling down on viral vector innovation. If it succeeds, it may unlock a new wave of decentralized gene therapy models built around outpatient, low-dose, and precise delivery.

  ASH 2025, BCMA, cancer gene therapy, in vivo CAR T therapy, lentiviral vectors, LV-169, multiple myeloma, oncology clinical trials, VV169, Vyriad